Mind + Muscle

technical minds + legal muscle


dig deep

Biosimilars Dodge Bullet As High Court Upholds ACA

  • 06.28.12
  • Jeff Overley
  • IP Law360

This article discusses the recent ruling of the U.S. Supreme Court in upholding the Affordable Care Act and the impact of the ruling on the biosimilars industry. In response to challengers of the decision's 12-year data exclusivity limit for original biologics, Paul Calvo was quoted saying, "“I think they can try, but I don’t see much of an avenue to get [exclusivity] changed."

Under the law, biosimilars are expected to be available in the U.S. in either 2014 or 2015. Had the law been struck down, according to Dr. Calvo, “It would have been a real mess.”

The full article is available for subscribers at IP Law360.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.